Stefan Schwabe compensation by year
Supernus Pharmaceuticals Summary Compensation Table · all 5 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Salary | $366,583 | $378,000 | $389,500 | $401,175 | $413,001 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 |
| Option awards | $353,530 | $679,776 | $695,815 | $885,020 | $703,268 |
| Non-equity incentive | $159,000 | $159,000 | $163,000 | $150,900 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $44,046 | $31,606 | $30,384 | $31,961 | $73,284 |
| Total | $923,159 | $1,248,382 | $1,278,699 | $1,469,056 | $1,189,554 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Supernus Pharmaceuticals, Inc. DEF 14A filed April 30, 2021, accession 0001104659-21-058739, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Supernus Pharmaceuticals, Inc. filed document, accession 0001104659-21-058739. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2021.
Supernus Pharmaceuticals’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Jack Khattar | Chief Executive Officer, President & Secretary | $6,669,046 |
| James Kelly | Former Executive Vice President, Chief Financial Officer | $1,801,636 |
| Stefan Schwabe · this page | Executive Vice President of Research and Development, Chief Medical Officer | $1,189,554 |
| Gregory Patrick | Senior Vice President, Chief Financial Officer | $1,152,802 |
| Padmanabh Bhatt | Senior Vice President, Intellectual Property, Chief Scientific Officer | $1,074,490 |
| Tami Martin | Senior Vice President, Regulatory Affairs | $804,637 |
The full Supernus Pharmaceuticals compensation record
free company briefThis page is one person within Supernus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Supernus Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Supernus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.